Dr Alexander Menzies is a Medical Oncologist and PhD student at Melanoma Institute Australia and The University of Sydney. He graduated with honours from The University of New South Wales in 2003, and completed specialist training in medical oncology at Westmead Hospital in 2011 that included a clinical trials fellowship in melanoma. He commenced postgraduate study in 2012, exploring biomarkers of response and resistance to targeted therapy in melanoma. He is an investigator on several clinical trials in melanoma, including the phase I trials of dabrafenib as monotherapy and in combination with trametinib, and has authored multiple publications in clinical and translational research in melanoma.
Abstracts this author is presenting: